| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Agios Pharmaceuticals, Inc. (AGIO) has 10 insiders with recent SEC Form 4 filings, including 0 buys and 27 sells. AGIO is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 149.1K | $5.32M | - | |
| Other | 67.7K | $2.42M | - | |
| CFO | 40.3K | $1.44M | - | |
| Other | 34.6K | $1.24M | - | |
| Dir | 17.8K | $635.2K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 3, 2017 | Biller Scott | Chief Scientific Officer | Sale+OE | 2,146 | $58.03 | $124,532.38 | -12.0% | |
| Apr 3, 2017 | Schenkein David P59 | Chief Executive Officer | Sale+OE | 3,000 | $58.62 | $175,860.00 | -100% | |
| Mar 23, 2017 | Cantley Lewis Clayton Jr. | Director | Sell | 2,036 | $53.11 | $108,131.96 | -0.5% | |
| Mar 20, 2017 | Biller Scott | Chief Scientific Officer | Sale+OE | 6,438 | $55.00 | $354,090.00 | -17.2% | |
| Mar 6, 2017 | Nelsen Robert | Director | Sell | 40,599 | $50.84 | $2,064,208.82 | -80.8% | |
| Mar 1, 2017 | Schenkein David P59 | Chief Executive Officer | Sale+OE | 3,000 | $50.47 | $151,410.00 | -100% | |
| Feb 28, 2017 | Nelsen Robert | Director | Sell | 243,082 | $49.36 | $11,997,895.83 | -30.1% | |
| Feb 23, 2017 | Nelsen Robert | Director | Sell | 135,364 | $49.37 | $6,683,463.66 | -6.2% | |
| Feb 16, 2017 | Schenkein David P59 | Chief Executive Officer | Sale+OE | 6,000 | $50.01 | $300,060.00 | -100% | |
| Nov 14, 2016 | Biller Scott | Chief Scientific Officer | Sale+OE | 32,500 | $65.00 | $2,112,500.00 | -37.5% |